The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.g

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Vahid B, Marik PE

Pulmonary complications of novel antineoplastic agents for solid tumors.

Chest. 2008;133(2):528-38

Hayes FA, Abromowitch M, Green AA

Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.

Cancer treatment reports. 1985;69(4):439-41

O'Dwyer PJ, King SA, Fortner CL, Leyland-Jones B

Hypersensitivity reactions to teniposide (VM-26): an analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1986;4(8):1262-9

Carstensen H, Nolte H, Hertz H

Teniposide-induced hypersensitivity reactions in children.

Lancet (London, England). 1989;2(8653):55

Siddall SJ, Martin J, Nunn AJ

Anaphylactic reactions to teniposide.

Lancet (London, England). 1989;1(8634):394

Kellie SJ, Crist WM, Pui CH, Crone ME, Fairclough DL, Rodman JH, Rivera GK

Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia.

Cancer. 1991;67(4):1070-5